← All companies
AMGEN INC
AMGN - CIK 0000318154
Market cap$183.41 B
Rank#79
SEC filings1,011
AMGEN INC trades as AMGN and has a market capitalization of $183.41 B, making it the #79 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $36.75B, up 10.0% from the prior year and net income of $7.71B. This page tracks AMGEN INC through 1,011 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$36.75BFY 2025
Net income (latest FY)$7.71BFY 2025
Operating cash flow (latest FY)$9.96BFY 2025
Total assets (latest FY)$90.59BFY 2025
Net margin21.0%latest FY
Financial performance
Over the last 9 fiscal years AMGEN INC's revenue grew from $22.99B to $36.75B, a compound annual growth rate of 5.4%. Net profit margin compressed from 33.6% to 21.0% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $183.41 B
- Share price (derived)market cap / shares outstanding
- $339.83
- P/E ratio (trailing FY)
- 23.8
- EPS (diluted)FY 2025
- $14.23
- Shares outstandingas of 2026-04-27
- 0.54B
- Total equityas of 2026-03-31
- $9.19B
- Return on equity
- 83.9%
- Long-term debtas of 2026-03-31
- $57.32B
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
Recent press releases
- AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH | Amgen Inc.2026-05-19
Clinical Trial Transparency, Data Sharing and Disclosure Practices
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE | Amgen Inc.2026-05-07
Clinical Trial Transparency, Data Sharing and Disclosure Practices
- AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR | Amgen Inc.2026-05-04
Clinical Trial Transparency, Data Sharing and Disclosure Practices
- AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS | Amgen Inc.2026-04-30
Clinical Trial Transparency, Data Sharing and Disclosure Practices
- Amgen Announces Webcast 2026 First Quarter Financial Results
Similar companies
The largest companies sharing AMGEN INC's SEC industry classification (biological products, (no diagnostic substances)).
Frequently asked questions
What is AMGEN INC's market cap?
AMGEN INC (AMGN) has a market capitalization of $183.41 B as of 2026-06-10, ranking #79 among US-listed companies.
How much revenue does AMGEN INC make?
AMGEN INC reported revenue of $36.75B for fiscal year 2025, an increase of 10.0% year over year.
Is AMGEN INC profitable?
Yes. AMGEN INC reported net income of $7.71B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.